On Monday, CytomX Therapeutics Inc (NASDAQ: CTMX) opened lower -5.20% from the last session, before settling in for the closing price of $2.5. Price fluctuations for CTMX have ranged from $0.40 to $3.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -124.50% at the time writing. With a float of $103.99 million, this company’s outstanding shares have now reached $157.54 million.
Let’s look at the performance matrix of the company that is accounted for 121 employees. In terms of profitability, gross margin is 64.9%, operating margin of 24.37%, and the pretax margin is 28.35%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CytomX Therapeutics Inc is 33.99%, while institutional ownership is 35.39%. The most recent insider transaction that took place on Jun 16 ’25, was worth 28,540. In this transaction Chief Financial Officer of this company sold 10,614 shares at a rate of $2.69, taking the stock ownership to the 226,271 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Chief Financial Officer sold 1,641 for $2.95, making the entire transaction worth $4,841. This insider now owns 199,385 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -124.50% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Check out the current performance indicators for CytomX Therapeutics Inc (CTMX). In the past quarter, the stock posted a quick ratio of 1.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.50, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 1.68 million, a negative change from its year-to-date volume of 3.43 million. As of the previous 9 days, the stock’s Stochastic %D was 85.94%.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 73.10%, which indicates a significant increase from 37.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.84% in the past 14 days, which was lower than the 169.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.01, while its 200-day Moving Average is $1.18. Nevertheless, the first resistance level for the watch stands at $2.44 in the near term. At $2.51, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.56. If the price goes on to break the first support level at $2.33, it is likely to go to the next support level at $2.28. The third support level lies at $2.21 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are currently 80,621K shares outstanding in the company with a market cap of 373.38 million. Presently, the company’s annual sales total 138,100 K according to its annual income of 31,870 K. Last quarter, the company’s sales amounted to 50,920 K and its income totaled 23,530 K.
